Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djae326 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Jaimie Z Shing und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Repressor Proteins, Human papillomavirus 16, Papillomavirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Intramural Research Program.
Abstract (Originalsprache)
Background
Human papillomavirus (HPV) type 16 E6 protein seropositivity accurately predicts oropharyngeal squamous cell carcinoma risk decades before diagnosis; but the biomarker’s translational potential is unknown. To inform considerations for oropharyngeal squamous cell carcinoma screening, we described HPV-16 E6 seroprevalence, predictors, and kinetics among cancer-free men.
Methods
In a cohort study in Brazil, Mexico, and the United States, we calculated HPV-16 E6 seropositivity (median fluorescence intensity > 1000), measured by multiplex serology, in cancer-free men. We assessed HPV-16 E6 seropositivity predictors using logistic regression, adjusting for country, age, sexual orientation, and lifetime number of sexual partners. Among HPV-16 E6 seropositive men, we retrieved all available retrospective serum samples and described temporal HPV-16 E6 antibody patterns.
Results
Of 3997 men, 14 had HPV-16 E6 antibodies detected (seroprevalence = 0.35%, 95% CI = 0.19% to 0.59%; median fluorescence intensity = 2407 [IQR = 1325-5986]). Older age was associated with increased odds of HPV-16 E6 seropositivity (50-84 years vs 18-29 years odds ratio = 16.61, 95% CI = 2.20 to 417.03). Serum from 11 of the 14 seropositive men retested positive; 6 men had median fluorescence intensity above 5000, of whom 2 had median fluorescence intensity greater than 10 000. Seven men had 3 or more years of follow-up; all were persistently seropositive for 3 years. One man was seropositive for 9 years but seroreverted at his exit visit. Oral HPV-16 DNA (prevalence = 1.13%) was associated with HPV-16 E6 seropositivity (odds ratio = 16.87, 95% CI = 3.35 to 69.55), but oral HPV-16 DNA positivity was not persistent over follow-up, even when HPV-16 E6 antibodies were persistently detected.
Conclusion
Although HPV-16 E6 seropositivity is rare, it is generally stable once detected; thus, HPV-16 E6 antibodies may be an informative biomarker of HPV-driven oropharyngeal squamous cell carcinoma. Few men seroreverted following HPV-16 E6 seropositivity but remained close to the seropositivity cutoff; thus, cancer risk among these men is less clear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States.
- Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, United States.
- Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
- Information Management Services, Silver Spring, MD 20705, United States.
ORCID-Profile: Jaimie Z Shing, Anna R Giuliano, Birgitta Michels, Allan Hildesheim, Sudhir Srivastava, Bradley A Sirak, John Schussler, Danping Liu, Tim Waterboer, Aimée R Kreimer
Förderung
- NCI NIH HHS
- NIH HHS
- Intramural Research Program
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Shing, J. Z., Giuliano, A. R., Brenner, N., Michels, B., Hildesheim, A., Srivastava, S., Sirak, B. A., Schussler, J., Liu, D., Wang, W., Waterboer, T., & Kreimer, A. R. (2025). Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae326
Vancouver
Shing JZ, Giuliano AR, Brenner N, Michels B, Hildesheim A, Srivastava S, et al. Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae326
BibTeX
@article{Shing2025,
author = {Shing, Jaimie Z and Giuliano, Anna R and Brenner, Nicole and Michels, Birgitta and Hildesheim, Allan and Srivastava, Sudhir and Sirak, Bradley A and Schussler, John and Liu, Danping and Wang, Wendy and Waterboer, Tim and Kreimer, Aimée R},
title = {Natural history of HPV-16 E6 serology among cancer-free men in a multicenter longitudinal cohort study},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djae326}
}
EUVIMED